| Drug Patent Number | Company | Drug Patent Title | Drug Patent Expiry | Activity Alert |
|---|---|---|---|---|
| These drug patents protects the active chemical substance. Only drug patent owner can launch products that use this active substance. | ||||
| USRE43932 | NOVARTIS | Crystal modification of a N-phenyl-2-pyrimidineamine derivative, processes for its manufacture and its use |
Jul, 2018
(5 years ago) | |
| These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc). | ||||
| US5521184 | NOVARTIS | Pyrimidine derivatives and processes for the preparation thereof |
Jan, 2015
(9 years ago) | |
|
US5521184 (Pediatric) | NOVARTIS | Pyrimidine derivatives and processes for the preparation thereof |
Jul, 2015
(8 years ago) | |
| US7544799 | NOVARTIS | Crystal modification of a N-phenyl-2-pyrimidineamine derivative, processes for its manufacture and its use |
Jan, 2019
(5 years ago) | |
| USRE43932 | NOVARTIS | Crystal modification of a N-phenyl-2-pyrimidineamine derivative, processes for its manufacture and its use |
Jan, 2019
(5 years ago) | |
| US6894051 | NOVARTIS | Crystal modification of a N-phenyl-2-pyrimidineamine derivative, processes for its manufacture and its use |
May, 2019
(4 years ago) | |
|
USRE43932 (Pediatric) | NOVARTIS | Crystal modification of a N-phenyl-2-pyrimidineamine derivative, processes for its manufacture and its use |
Jul, 2019
(4 years ago) | |
|
US7544799 (Pediatric) | NOVARTIS | Crystal modification of a N-phenyl-2-pyrimidineamine derivative, processes for its manufacture and its use |
Jul, 2019
(4 years ago) | |
|
US6894051 (Pediatric) | NOVARTIS | Crystal modification of a N-phenyl-2-pyrimidineamine derivative, processes for its manufacture and its use |
Nov, 2019
(4 years ago) | |
| US6958335 | NOVARTIS | Treatment of gastrointestinal stromal tumors |
Dec, 2021
(2 years ago) | |
|
US6958335 (Pediatric) | NOVARTIS | Treatment of gastrointestinal stromal tumors |
Jun, 2022
(1 year, 10 months ago) | |
Gleevec is owned by Novartis.
Gleevec contains Imatinib Mesylate.
Gleevec has a total of 11 drug patents out of which 11 drug patents have expired.
Expired drug patents of Gleevec are:
- US5521184
- US5521184*PED
- US7544799
- USRE43932
- USRE43932*PED
- US6894051
- US7544799*PED
- US6894051*PED
- US6958335
- US6958335*PED
- USRE43932
Gleevec was authorised for market use on 10 May, 2001.
Gleevec is available in tablet;oral, capsule;oral dosage forms.
Gleevec can be used as gleevec is also indicated for the treatment of patients with kit (cd117) positive unresectable and/or metastatic malignant gastrointestinal stromal tumors (gist), a method for treating a tumor disease.
The generics of Gleevec are possible to be released after 19 June, 2022.
Drugs and Companies using IMATINIB MESYLATE ingredient
Market Authorisation Date: 10 May, 2001
Treatment: A method for treating a tumor disease; Gleevec is also indicated for the treatment of patients with kit (cd117) positive unresectable and/or metastatic malignant gastrointestinal stromal tumors (gist)
Dosage: CAPSULE;ORAL; TABLET;ORAL
GLEEVEC family patents
